Skip to main content
Top
Published in: International Urology and Nephrology 1/2008

01-03-2008 | Original Article

Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis

Authors: Mufazzal Ahmad, Tarun Jeloka, Theodoros Pliakogiannis, Shruti Tapiawala, Hui Zhong, Joanne M. Bargman, Dimitrios Oreopoulos

Published in: International Urology and Nephrology | Issue 1/2008

Login to get access

Abstract

A preliminary report from our unit previously suggested that diabetic patients on continuous cyclic peritoneal dialysis (CCPD) have higher ultrafiltration (UF) with icodextrin than non-diabetic patients. To confirm this observation, we did a retrospective analysis of our patients (17 diabetic and 23 non-diabetic) who were on stable CCPD prescription using a long-day dwell with icodextrin. We collected daily UF data from these patients’ records for 30 days. The two groups showed no significant difference with respect to age, gender, hemoglobin, serum albumin, peritoneal dialysis and icodextrin vintage, peritoneal membrane characteristics, CCPD prescription, and peritoneal and residual renal clearance. The overnight net UF achieved with the cycler with standard glucose dialysate was similar in the two groups (850 ± 379 in diabetic vs 713 ± 484 ml/day in non-diabetic, P = 0.34). However, UF with icodextrin during the day dwell (14.8 ± 0.8 h) was significantly higher in diabetics than non-diabetics (348 ± 198 vs 137 ± 311 ml/day, P = 0.02). Our results show that icodextrin produces significantly higher UF in long-day dwell in diabetic ESRD patients on CCPD than in non-diabetic patients. The reason for this difference is not clear.
Literature
1.
go back to reference Chung SH, Stenvinkel P, Bergstrom J, Lindholm B (2000) Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 20(Suppl 5):S57–S67PubMed Chung SH, Stenvinkel P, Bergstrom J, Lindholm B (2000) Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 20(Suppl 5):S57–S67PubMed
2.
go back to reference Wolfson M, Piraino B, Hamburger RJ, Morton AR, Icodextrin Study Group (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40(5):1055–1065PubMedCrossRef Wolfson M, Piraino B, Hamburger RJ, Morton AR, Icodextrin Study Group (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40(5):1055–1065PubMedCrossRef
3.
go back to reference Mistry CD, Gokal R, Peers E (1994) A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46(2):496–503PubMedCrossRef Mistry CD, Gokal R, Peers E (1994) A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46(2):496–503PubMedCrossRef
4.
go back to reference Martikainen T, Ekstrand A, Honkanen E, Teppo AM, Gronhagen-Riska C (2005) Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? Scand J Urol Nephrol 39(5):410–416PubMedCrossRef Martikainen T, Ekstrand A, Honkanen E, Teppo AM, Gronhagen-Riska C (2005) Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? Scand J Urol Nephrol 39(5):410–416PubMedCrossRef
5.
go back to reference Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW (2003) Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 64:1480–1486PubMedCrossRef Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW (2003) Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 64:1480–1486PubMedCrossRef
6.
go back to reference Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM (2000) Effects of icodextrin in automated peritoneal dialysis on blood pressure and biolelectrical impedance analysis. Nephrol Dial Transplant 15:862–866PubMedCrossRef Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM (2000) Effects of icodextrin in automated peritoneal dialysis on blood pressure and biolelectrical impedance analysis. Nephrol Dial Transplant 15:862–866PubMedCrossRef
7.
go back to reference Van V, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, Van B, Lefebvre RA, De V, Lameire NH (2002) Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 22:32–38PubMed Van V, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, Van B, Lefebvre RA, De V, Lameire NH (2002) Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 22:32–38PubMed
8.
go back to reference Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC (2003) Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double blind randomized controlled trial. J Am Soc Nephrol 14(9):2338–2344PubMedCrossRef Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimburger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC (2003) Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double blind randomized controlled trial. J Am Soc Nephrol 14(9):2338–2344PubMedCrossRef
9.
go back to reference Jeloka TK, Oreopoulos DG (2006) Is ultrafiltration with icodextrin higher in diabetics than in non-diabetics? Perit Dial Int 26(6):729–730PubMed Jeloka TK, Oreopoulos DG (2006) Is ultrafiltration with icodextrin higher in diabetics than in non-diabetics? Perit Dial Int 26(6):729–730PubMed
10.
go back to reference Twardowski ZJ, Nolph KD, Khanna R et al (1987) Peritoneal equilibration test. Perit Dial Bull 7:138–147 Twardowski ZJ, Nolph KD, Khanna R et al (1987) Peritoneal equilibration test. Perit Dial Bull 7:138–147
11.
go back to reference Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S (2005) Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 16(2):546–554PubMedCrossRef Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S (2005) Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 16(2):546–554PubMedCrossRef
12.
go back to reference Willie ME, Plant MJ, Edwards L, Brown CB (1997) Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 17(1):84–87 Willie ME, Plant MJ, Edwards L, Brown CB (1997) Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 17(1):84–87
13.
go back to reference Imholz AL, Brown CB, Koomen GC, Arisz L, Krediet RT (1993) The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 9:25–30PubMed Imholz AL, Brown CB, Koomen GC, Arisz L, Krediet RT (1993) The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 9:25–30PubMed
14.
go back to reference Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW (2005) Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton) 10:33–36CrossRef Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW (2005) Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton) 10:33–36CrossRef
Metadata
Title
Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis
Authors
Mufazzal Ahmad
Tarun Jeloka
Theodoros Pliakogiannis
Shruti Tapiawala
Hui Zhong
Joanne M. Bargman
Dimitrios Oreopoulos
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2008
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-007-9298-3

Other articles of this Issue 1/2008

International Urology and Nephrology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine